GlassScriptPhysician profile
Ronald D Mcfadden
NPI 1285718734
$76,667.45
in general payments reported to CMS, 2019-2025
27 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $1,048 · 2021: $3,304 · 2022: $20K · 2023: $30K · 2024: $19K · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $6,569 · Travel and Lodging: $1,791 · Education: $86.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,500.00 |
| Food and Beverage | $6,569.44 |
| Travel and Lodging | $1,790.73 |
| Education | $86.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67,562.90 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,007.78 | 2019-2025 | Trintellix |
| Lundbeck LLC | $810.90 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $804.20 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $718.09 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $712.03 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $660.56 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $627.58 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $625.86 | 2021-2025 | Aristada, Lybalvi |
| Allergan, INC. | $581.28 | 2019-2020 | |
| Corium, LLC | $520.29 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $492.25 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $369.31 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $254.81 | 2021-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $138.96 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $136.25 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $111.90 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $102.85 | 2019-2021 | |
| Eisai INC. | $94.49 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $80.78 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $60.95 | 2019-2025 | Invega Sustenna |
| Bausch Health US, LLC | $48.31 | 2019-2022 | |
| Shire North American Group INC | $44.17 | 2019 | |
| Almatica Pharma LLC | $31.93 | 2021-2022 | |
| Tris Pharma INC | $29.92 | 2019-2021 | |
| Owp Pharmaceuticals, INC. | $25.93 | 2022 | |
| Adlon Therapeutics L.P. | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.